Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
An epigenomic ctDNA assay reading methylation signatures predicts recurrence in resected melanoma, potentially guiding adjuvant therapy and follow-up decisions.
Topic
Adjuvant Therapy
Topic
Adjuvant Therapy
Chronic Toxicity After Adjuvant Anti-PD-1 in Melanoma Under Scrutiny
Melanoma survivors treated with adjuvant anti-PD-1 face persistent immune-related toxicities; Andrea Boutros examines the long-te…
Personalised mRNA Vaccine Stops Melanoma Returning in Reported Breakthrough
A personalised mRNA cancer vaccine stopped melanoma from returning, Gavi reports, marking a milestone for individualised neoantig…
Natera Launches Randomized Signatera-Guided Interventional Melanoma Study
Natera will run a randomized interventional melanoma study using its tumor-informed Signatera ctDNA assay to guide treatment, shi…
Immunotherapy Shows Promise for Clearing Residual Melanoma Cells
Cornell Chronicle reports immunotherapy may clear residual melanoma cells persisting after surgery, an early but mechanistically…
Adjuvant Melanoma Drug Cuts Recurrence Risk in Reported Trial
A new drug has shown it can prevent recurrence of deadly melanoma, with Australian broadcasters calling the result a landmark for…
Moderna–Merck Melanoma Combo Cuts Spread Risk at Five Years
Moderna and Merck report their mRNA cancer vaccine–pembrolizumab combination cut the risk of melanoma spread at five years, a dur…